OBJECTIVE: To assess the incidence and type of potential, clinically significant drug-drug interactions in elderly outpatients with arterial hypertension. SETTING: Three community pharmacies in Croatia. METHOD: Eligible patients were aged 65 or older, treated for arterial hypertension and received 2 or more drugs. Potential interactions were identified by Lexi-Interact software. The software categorized each potential interaction according to clinical significance in five groups: (A) No known interaction; (B) Specified agents may interact, but there is little to no evidence of clinical concern; (C) Specified agents may interact in a clinically significant manner. Monitoring therapy is suggested; (D) The two medications may interact in a clinically significant manner. Modification of therapy is suggested; (X) Contraindicated combination. Interactions of level C, D and X were considered clinically significant. MAIN OUTCOME MEASURE: The incidence and type of potential drug-drug interactions. RESULTS: There were 265 patients included in the study. Potential, clinically significant drug interactions were identified in 240 (90.6%) patients, out of which 97.9% had interactions with clinical significance C, 20.4% D, and 0.8% X. The median number of drug interactions per patient was 4. We identified 215 drug combinations with the potential to cause clinically significant interaction, out of which 83.3% had clinical significance C, 16.3% clinical significance D, and 0.4% clinical significance X. CONCLUSION: Drug-drug interactions are common in elderly hypertensive patients. Computer-based screening could help pharmacists and physicians to recognize potential, clinically significant interactions.
OBJECTIVE: To assess the incidence and type of potential, clinically significant drug-drug interactions in elderly outpatients with arterial hypertension. SETTING: Three community pharmacies in Croatia. METHOD: Eligible patients were aged 65 or older, treated for arterial hypertension and received 2 or more drugs. Potential interactions were identified by Lexi-Interact software. The software categorized each potential interaction according to clinical significance in five groups: (A) No known interaction; (B) Specified agents may interact, but there is little to no evidence of clinical concern; (C) Specified agents may interact in a clinically significant manner. Monitoring therapy is suggested; (D) The two medications may interact in a clinically significant manner. Modification of therapy is suggested; (X) Contraindicated combination. Interactions of level C, D and X were considered clinically significant. MAIN OUTCOME MEASURE: The incidence and type of potential drug-drug interactions. RESULTS: There were 265 patients included in the study. Potential, clinically significant drug interactions were identified in 240 (90.6%) patients, out of which 97.9% had interactions with clinical significance C, 20.4% D, and 0.8% X. The median number of drug interactions per patient was 4. We identified 215 drug combinations with the potential to cause clinically significant interaction, out of which 83.3% had clinical significance C, 16.3% clinical significance D, and 0.4% clinical significance X. CONCLUSION: Drug-drug interactions are common in elderly hypertensivepatients. Computer-based screening could help pharmacists and physicians to recognize potential, clinically significant interactions.
Authors: Andrew C Stafford; Peter C Tenni; Gregory M Peterson; Shane L Jackson; Anne Hejlesen; Christine Villesen; Mette Rasmussen Journal: Pharm World Sci Date: 2009-02-26
Authors: Jerry H Gurwitz; Terry S Field; Leslie R Harrold; Jeffrey Rothschild; Kristin Debellis; Andrew C Seger; Cynthia Cadoret; Leslie S Fish; Lawrence Garber; Michael Kelleher; David W Bates Journal: JAMA Date: 2003-03-05 Impact factor: 56.272
Authors: J Doucet; P Chassagne; C Trivalle; I Landrin; M D Pauty; N Kadri; J F Ménard; E Bercoff Journal: J Am Geriatr Soc Date: 1996-08 Impact factor: 5.562
Authors: Carlos Chiatti; Silvia Bustacchini; Gianluca Furneri; Lorenzo Mantovani; Marco Cristiani; Clementina Misuraca; Fabrizia Lattanzio Journal: Drug Saf Date: 2012-01 Impact factor: 5.606